TUDORZA PRESSAIR
LAMA DPI
Aclidinium bromide · Covis Pharma (an Azurity Pharmaceuticals company)
Active Medication & Mechanism
- Aclidinium bromide LAMA400 mcg per actuation (delivers 375 mcg from mouthpiece)
Long-acting muscarinic antagonist. Blocks M3 muscarinic receptors on airway smooth muscle, reducing cholinergic bronchoconstriction. Rapidly hydrolyzed in plasma, reducing systemic anticholinergic effects.
FDA-Approved Dosing — Strength × Indication
Strength Regimen COPDAsthma
400 mcg
1 inhalation twice daily (morning and evening) → 800 mcg
FDA Approved
Long-term maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema.
Not Approved
Tudorza Pressair is NOT indicated for asthma.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
400 mcg 1 inhalation twice daily (morning and evening) → 800 mcg
COPD FDA Approved
Long-term maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema.
Asthma Not Approved
Tudorza Pressair is NOT indicated for asthma.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
Not a rescue inhaler. Not for acute bronchospasm. Use a SABA.